Title: Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer. Two Case Reports
Authors: Vandenput, I ×
Vanden Bempt, Isabelle
Leunen, K
Neven, Patrick
Berteloot, Patrick
Moerman, Philippe
Vergote, Ignace
Amant, Frédéric #
Issue Date: Oct-2009
Publisher: Karger
Series Title: Gynecologic and obstetric investigation vol:67 issue:1 pages:46-48
Abstract: Background: It is hypothesized that the HER-2/neu receptor could be used for targeted therapy in recurrent endometrial cancer. Cases: A patient with type II endometrial cancer (serous), showing strong HER-2/neu overexpression and gene amplification in both primary and recurrent tumor, received single-agent trastuzumab (3x weekly, 8 mg/kg loading, 6 mg/kg maintenance dose). Because of progression after 4 cycles, weekly paclitaxel-trastuzumab (80 mg/m(2) paclitaxel; trastuzumab 4 mg/kg loading, 2 mg/kg maintenance dose) was initiated. However, progressive disease was also noted after 11 weeks of combined treatment. A second patient, with recurrent type II endometrial cancer (grade III endometrioid), had HER-2/neu gene amplification in the primary tumor. However, biopsy from a lung metastasis 3 years later appeared to be HER-2/neu-negative. Conclusion: Based on lack of response and changes in tumor biology, trastuzumab was of little clinical value in 2 cases of recurrent type II endometrial cancer. This report underscores the importance of reassessment of a recurrent tumor before initiating targeted treatment.
ISSN: 0378-7346
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
Translational Cell & Tissue Research
Section Woman - Miscellaneous (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science